Frontiers in cellular and infection microbiology · 2026
Carbapenemase-directed therapy: optimizing antibiotic combinations against carbapenem-resistant Klebsiella pneumoniae.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Wen-Bo, Wei Yi-Fei, Zhang Yu-Ying, Guo Qing-Li, Shi Lin, Fan Peng-Li, Wang Shan-Mei
Аннотация
OBJECTIVE: Given the limited therapeutic options for infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP) due to multidrug resistance, this study aimed to evaluate combination therapeutic strategies based on carbapenemase profiles and resistance phenotypes.
METHODS: The in vitro activities of ceftazidime-avibactam (CZA) and polymyxin B (PMB)-based combinations was systematically evaluated against 139 CRKP isolates, including K. pneumoniae carbapenemase (KPC) producing strains, New Delhi metallo-β-lactamase (NDM), and KPC and NDM co-producing carbapenem-resistant K. pneumoniae strains (KN-CRKP). The combination effects of these antimicrobial combinations were assessed using the fractional inhibitory concentration index (FICI) and susceptibility breakpoint index (SBPI).
RESULTS: Among CZA-resistant KPC-CRKP isolates, combinations of CZA with β-lactams exhibited high synergy rates (79.7-86.5%). In PMB-resistant KPC-CRKP, PMB + CZA demonstrated substantially higher synergy rates (53.2%) than conventional PMB-carbapenem combinations (≤3.8%). Against NDM-CRKP, CZA + aztreonam (ATM) showed synergistic activity in 83.3% of isolates. Notably, in KN-CRKP, CZA + ATM produced synergistic or additive effects in all isolates, despite resistance to the individual agents. SBPI analysis further suggested substantial antimicrobial enhancement in some combinations classified as indifferent by FICI, including PMB + tigecycline (TGC).
CONCLUSIONS: Carbapenemase profiles substantially influence the efficacy of combination therapies against CRKP. CZA-based combinations, particularly those combined with β-lactams or ATM, demonstrated favorable in vitro activity against KPC and NDM-producing CRKP, while PMB in combination with CZA partially restored activity in PMB-resistance isolates. Notably, the CZA-ATM regimen showed consistently favorable activity against both NDM-CRKP and KPC-NDM co-producing isolates. These findings support the potential value of carbapenemase profile-guided combination therapy for optimizing treatment of highly resistant CRKP infections.
METHODS: The in vitro activities of ceftazidime-avibactam (CZA) and polymyxin B (PMB)-based combinations was systematically evaluated against 139 CRKP isolates, including K. pneumoniae carbapenemase (KPC) producing strains, New Delhi metallo-β-lactamase (NDM), and KPC and NDM co-producing carbapenem-resistant K. pneumoniae strains (KN-CRKP). The combination effects of these antimicrobial combinations were assessed using the fractional inhibitory concentration index (FICI) and susceptibility breakpoint index (SBPI).
RESULTS: Among CZA-resistant KPC-CRKP isolates, combinations of CZA with β-lactams exhibited high synergy rates (79.7-86.5%). In PMB-resistant KPC-CRKP, PMB + CZA demonstrated substantially higher synergy rates (53.2%) than conventional PMB-carbapenem combinations (≤3.8%). Against NDM-CRKP, CZA + aztreonam (ATM) showed synergistic activity in 83.3% of isolates. Notably, in KN-CRKP, CZA + ATM produced synergistic or additive effects in all isolates, despite resistance to the individual agents. SBPI analysis further suggested substantial antimicrobial enhancement in some combinations classified as indifferent by FICI, including PMB + tigecycline (TGC).
CONCLUSIONS: Carbapenemase profiles substantially influence the efficacy of combination therapies against CRKP. CZA-based combinations, particularly those combined with β-lactams or ATM, demonstrated favorable in vitro activity against KPC and NDM-producing CRKP, while PMB in combination with CZA partially restored activity in PMB-resistance isolates. Notably, the CZA-ATM regimen showed consistently favorable activity against both NDM-CRKP and KPC-NDM co-producing isolates. These findings support the potential value of carbapenemase profile-guided combination therapy for optimizing treatment of highly resistant CRKP infections.
Предметные рубрики MeSH
Klebsiella pneumoniaebeta-LactamasesMicrobial Sensitivity TestsAnti-Bacterial AgentsBacterial ProteinsHumansCeftazidimeDrug CombinationsKlebsiella InfectionsAzabicyclo CompoundsPolymyxin BDrug SynergismCarbapenem-Resistant EnterobacteriaceaeCarbapenemsDrug Resistance, Multiple, BacterialDrug Therapy, Combination